FR19C1028I2 - Anticorps greffes avec cdr humains et fragments de ces anticorps - Google Patents

Anticorps greffes avec cdr humains et fragments de ces anticorps

Info

Publication number
FR19C1028I2
FR19C1028I2 FR19C1028C FR19C1028C FR19C1028I2 FR 19C1028 I2 FR19C1028 I2 FR 19C1028I2 FR 19C1028 C FR19C1028 C FR 19C1028C FR 19C1028 C FR19C1028 C FR 19C1028C FR 19C1028 I2 FR19C1028 I2 FR 19C1028I2
Authority
FR
France
Prior art keywords
antibodies
grafted
fragments
human
ccr4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR19C1028C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of FR19C1028I1 publication Critical patent/FR19C1028I1/fr
Application granted granted Critical
Publication of FR19C1028I2 publication Critical patent/FR19C1028I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4719—G-proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
FR19C1028C 2001-08-31 2019-04-19 Anticorps greffes avec cdr humains et fragments de ces anticorps Active FR19C1028I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001265144 2001-08-31
PCT/JP2002/008828 WO2003018635A1 (en) 2001-08-31 2002-08-30 Human cdr-grafted antibodies and antibody fragments thereof

Publications (2)

Publication Number Publication Date
FR19C1028I1 FR19C1028I1 (de) 2019-05-17
FR19C1028I2 true FR19C1028I2 (fr) 2021-02-19

Family

ID=19091652

Family Applications (1)

Application Number Title Priority Date Filing Date
FR19C1028C Active FR19C1028I2 (fr) 2001-08-31 2019-04-19 Anticorps greffes avec cdr humains et fragments de ces anticorps

Country Status (23)

Country Link
US (8) US7504104B2 (de)
EP (1) EP1449850B9 (de)
JP (1) JP4052515B2 (de)
KR (1) KR100959248B1 (de)
CN (1) CN100430420C (de)
AT (1) ATE490277T1 (de)
AU (1) AU2002338015B8 (de)
BE (1) BE2019C006I2 (de)
BR (1) BRPI0212266B8 (de)
CA (1) CA2458627C (de)
CO (1) CO5560582A2 (de)
CY (2) CY1111193T1 (de)
DE (1) DE60238503D1 (de)
DK (1) DK1449850T3 (de)
ES (1) ES2356190T3 (de)
FR (1) FR19C1028I2 (de)
HK (1) HK1073851A1 (de)
LU (1) LUC00116I2 (de)
MX (1) MXPA04001894A (de)
NL (1) NL300985I2 (de)
NO (1) NO334858B1 (de)
PT (1) PT1449850E (de)
WO (1) WO2003018635A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2264166B1 (de) * 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. VERFAHREN ZUR KONTROLLE DER AKTIVITäT VON IMMUNOLOGISCH FUNKTIONELLEM MOLEKüL
DE60134962D1 (de) 2000-03-03 2008-09-04 Kyowa Hakko Kogyo Kk Anti-ccr4 antikörper und fragmente davon
US6946292B2 (en) * 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20050095242A1 (en) * 2002-02-28 2005-05-05 Ryuzo Ueda Diagnostics and remedies for interstitial pneumonia
EP1500400A4 (de) 2002-04-09 2006-10-11 Kyowa Hakko Kogyo Kk Arzneimittel mit antikörper-zusammensetzung
PL1698640T5 (pl) 2003-10-01 2019-12-31 Kyowa Hakko Kirin Co., Ltd. Sposób stabilizacji przeciwciała i stabilizowany preparat przeciwciała w postaci roztworu
WO2005035582A1 (ja) * 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Ｃｃｒ４に特異的に結合する抗体組成物
WO2005053741A1 (ja) 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. ケモカイン受容体ｃｃｒ４に対する遺伝子組換え抗体を含む医薬
KR101627588B1 (ko) 2003-12-23 2016-06-07 제넨테크, 인크. 신규 항-ｉｌ１３ 항체 및 그 용도
US20060034841A1 (en) * 2004-06-07 2006-02-16 Kyowa Hakko Kogyo Co., Ltd. Method of depleting regulatory T cell
EP1871807B1 (de) 2005-02-18 2012-11-28 Dana-Farber Cancer Institute, Inc. Antikörper gegen cxcr4 und anwendungsverfahren dafür
WO2007013627A1 (ja) * 2005-07-28 2007-02-01 Kyowa Hakko Kogyo Co., Ltd. Bリンパ腫およびホジキンリンパ腫の治療剤
US20080118978A1 (en) 2006-04-28 2008-05-22 Takashi Sato Anti-tumor agent
GB0718167D0 (en) * 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
WO2009086514A1 (en) * 2007-12-28 2009-07-09 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
JP5552630B2 (ja) * 2008-10-24 2014-07-16 学校法人 聖マリアンナ医科大学 Ｈｔｌｖ−ｉ関連脊髄症を治療または予防するための医薬、およびｈｔｌｖ−ｉ関連脊髄症の患者に対する抗体療法の効果を試験する方法
GB0909906D0 (en) 2009-06-09 2009-07-22 Affitech As Antibodies
EP2476438B1 (de) * 2009-09-10 2014-07-23 Kyowa Hakko Kirin Co., Ltd. Medikament mit einer spezifisch an den menschlichen cc-chemokin-rezeptor 4 (ccr4) gebundenen antikörperzusammensetzung
CN102863533B (zh) * 2010-06-21 2013-12-11 中国科学技术大学 抗体人源化改造方法
EA201370030A1 (ru) 2010-08-10 2013-06-28 Амген Инк. Бифункциональный количественный анализ in vitro связывания мишени для обнаружения нейтрализующих антител к антителам-мишеням
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
US10266599B2 (en) 2010-12-07 2019-04-23 Cancer Research Technology Limited Antibodies which bind to the human CC chemokine receptor 4 and uses thereof
EP3447491A3 (de) 2010-12-16 2019-06-05 F. Hoffmann-La Roche AG Diagnose und behandlungen im zusammenhang mit th2-hemmung
EP2723380B1 (de) 2011-06-24 2019-08-21 Stephen D. Gillies Leichtkettige immunglobulin- fusionsproteine und verfahren zu ihrer anwendung
MX365592B (es) * 2012-07-06 2019-06-07 Univ School St Marianna Medicine Anticuerpo para reducir células infectadas con el virus de htlv-1.
CN105722992B (zh) 2013-09-13 2021-04-20 豪夫迈·罗氏有限公司 用于检测和定量细胞系和重组多肽产物中的宿主细胞蛋白的组合物和方法
EP4331605A3 (de) 2013-09-13 2024-05-22 F. Hoffmann-La Roche AG Verfahren und zusammensetzungen mit gereinigten rekombinanten polypeptiden
AU2015264528A1 (en) 2014-05-21 2016-11-03 Kyowa Hakko Kirin Co., Ltd. Combination of an anti-CCR4 antibody and a 4-1BB agonist for treating cancer
CA2992238A1 (en) 2015-07-14 2017-01-19 Kyowa Hakko Kirin Co., Ltd. A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
SG11202005557TA (en) 2017-12-12 2020-07-29 Macrogenics Inc Bispecific cd 16-binding molecules and their use in the treatment of disease
CN108250290B (zh) * 2018-02-23 2024-03-12 上海捌加壹医药科技有限公司 Ccr4的n端重组蛋白及其用途
CN116731186B (zh) * 2023-07-07 2023-12-26 武汉爱博泰克生物科技有限公司 抗人IgG-Fc兔单克隆抗体及其制备方法、多核苷酸分子、表达载体和宿主细胞

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5608039A (en) * 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
US5914110A (en) 1993-09-07 1999-06-22 Smithkline Beecham Corporation Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders
JPH0853355A (ja) 1994-08-12 1996-02-27 Taisho Pharmaceut Co Ltd Ｉｌ−５産生抑制剤
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
IL125658A0 (en) 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
KR100440836B1 (ko) 1997-11-12 2004-07-19 에프. 호프만-라 로슈 아게 레티노이드 길항제를 이용한 제2형 ｔ-보조세포 중재 면역질환의 치료
US6355244B1 (en) 1997-11-17 2002-03-12 University Of Kentucky Research Foundation Methods and compositions for the treatment of psoriasis
BR9912223A (pt) 1998-06-26 2001-04-24 Chugai Pharmaceutical Co Ltd Agente terapêutico para crise hipercalcêmica
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
US6488930B1 (en) 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
EP1050307A1 (de) 1999-05-06 2000-11-08 Applied Research Systems ARS Holding N.V. CCR4 Antagoniste in Sepsis
DE60134962D1 (de) * 2000-03-03 2008-09-04 Kyowa Hakko Kogyo Kk Anti-ccr4 antikörper und fragmente davon
WO2005053741A1 (ja) * 2003-12-04 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. ケモカイン受容体ｃｃｒ４に対する遺伝子組換え抗体を含む医薬

Also Published As

Publication number Publication date
BR0212266A (pt) 2004-10-19
US8143058B2 (en) 2012-03-27
JPWO2003018635A1 (ja) 2004-12-09
US7842797B2 (en) 2010-11-30
US20180030146A1 (en) 2018-02-01
CN100430420C (zh) 2008-11-05
US20130273038A1 (en) 2013-10-17
US10131711B2 (en) 2018-11-20
MXPA04001894A (es) 2005-09-08
ES2356190T3 (es) 2011-04-05
AU2002338015B8 (en) 2008-03-20
FR19C1028I1 (de) 2019-05-17
CO5560582A2 (es) 2005-09-30
US7504104B2 (en) 2009-03-17
CA2458627A1 (en) 2003-03-06
KR20040044492A (ko) 2004-05-28
JP4052515B2 (ja) 2008-02-27
LUC00116I1 (de) 2019-05-02
LUC00116I2 (de) 2019-12-27
HK1073851A1 (en) 2005-10-21
ATE490277T1 (de) 2010-12-15
AU2002338015B2 (en) 2008-02-07
EP1449850A4 (de) 2005-08-10
US20030175273A1 (en) 2003-09-18
EP1449850A1 (de) 2004-08-25
US20090227012A1 (en) 2009-09-10
CA2458627C (en) 2013-09-10
CY2019022I2 (el) 2019-11-27
US20150315285A1 (en) 2015-11-05
PT1449850E (pt) 2011-02-02
US8900584B2 (en) 2014-12-02
CN1575303A (zh) 2005-02-02
BRPI0212266B1 (pt) 2020-05-05
NL300985I1 (en) 2019-05-08
NO334858B1 (no) 2014-06-23
DE60238503D1 (de) 2011-01-13
DK1449850T3 (da) 2011-02-14
US9051371B2 (en) 2015-06-09
NL300985I2 (en) 2019-11-21
EP1449850B9 (de) 2011-05-11
KR100959248B1 (ko) 2010-05-26
EP1449850B1 (de) 2010-12-01
WO2003018635A1 (en) 2003-03-06
CY1111193T1 (el) 2015-06-11
US10590203B2 (en) 2020-03-17
BRPI0212266B8 (pt) 2021-05-25
NO20040976L (no) 2004-06-01
US20120177643A1 (en) 2012-07-12
BE2019C006I2 (de) 2021-11-22
US20140186349A1 (en) 2014-07-03
US20110059524A1 (en) 2011-03-10
CY2019022I1 (el) 2019-11-27

Similar Documents

Publication Publication Date Title
FR19C1028I2 (fr) Anticorps greffes avec cdr humains et fragments de ces anticorps
EP1238985A4 (de) Menschlicher antikörper gegen gangliosid gd3 für die transplantationskomplementarität bestimmente regionund derivate des antikörpers gegen das gangliosid gd3
WO2004050016A3 (en) Delivery of pharmaceutical agents via the human insulin receptor
TR200102733T2 (tr) IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
MXPA02010801A (es) Agentes diagnosticos, de representacion y terapeuticos cationicos asociados con sitios vasculares activados.
HUP0303952A2 (hu) Terápiás ágens gyermekkori krónikus artrítiszhez hasonló betegségekre
WO2003009815A3 (en) Compositions and methods for modulating blood-brain barrier transport
EA200101156A1 (ru) ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НОВОГО ТИПА НА ОСНОВЕ ОБЛАДАЮЩИХ ХОЛИНЕРГИЧЕСКИМ ДЕЙСТВИЕМ СОЕДИНЕНИЙ И β-МИМЕТИКОВ
EP1140170A4 (de) Neue substanzen und methoden zur behandlung und diagnose von okularen krankheiten
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
DK0841949T3 (da) Anvendelse af saccharid-konjugater
EE200300295A (et) Kinuklidiinkarbamaadi derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette nähtud respiratoorsete, kuseelundite või mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon
EP0671920A4 (de) Ein anti-idiotypischer antikörper und seine verwendung in der diagnose und therapie von hiv-verwandten krankheiten.
BR0308090A (pt) conjugados de agentes citotóxicos ou terapêuticos e peptìdios biologicamente ativos
DZ2887A1 (fr) Dérivés d'azétidine, leur préparation et les médicaments les contenant.
FR2793678B1 (fr) Manchon elastique a garniture viscoelastique pour la protection ou le soin de doigts ou d'orteils
DE60138867D1 (de) Medikament zum Schutz gegen thrombotische Krankheiten
AU2003290015A1 (en) Mastitis treatment
DE60040555D1 (de) Küle
TR200202109T2 (tr) 5-[{6-(2-Flüorobenzil)oksi-2-naftil}metil]-2,4-tiyazolidin dion kristalleri
EP2266558A3 (de) Behandlung neuropathischen Schmerzes mit N-Methyl-D-Aspartat (NMDA) -Rezeptorantagonisten
EP0811385A3 (de) Konjugate von einem Interleukin-2 Rezeptor spezifisch erkennenden Faktor mit Ribonuklease